The science and clinical applications of intermittent fasting


For many people, the New Year is a time to adopt new habits as a renewed commitment to personal health.

Newly enthusiastic fitness buffs pack into gyms and grocery stores are filled with shoppers eager to try out new diets.

But, does scientific evidence support the claims made for these diets?

In a review article published in the Dec. 26 issue of The New England Journal of Medicine, Johns Hopkins Medicine neuroscientist Mark Mattson, Ph.D., concludes that intermittent fasting does.

Mattson, who has studied the health impact of intermittent fasting for 25 years, and adopted it himself about 20 years ago, writes that “intermittent fasting could be part of a healthy lifestyle.”

A professor of neuroscience at the Johns Hopkins University School of Medicine, Mattson says his new article is intended to help clarify the science and clinical applications of intermittent fasting in ways that may help physicians guide patients who want to try it.

Intermittent fasting diets, he says, fall generally into two categories: daily time-restricted feeding, which narrows eating times to 6-8 hours per day, and so-called 5:2 intermittent fasting, in which people limit themselves to one moderate-sized meal two days each week.

An array of animal and some human studies have shown that alternating between times of fasting and eating supports cellular health, probably by triggering an age-old adaptation to periods of food scarcity called metabolic switching.

Such a switch occurs when cells use up their stores of rapidly accessible, sugar-based fuel, and begin converting fat into energy in a slower metabolic process.

Mattson says studies have shown that this switch improves blood sugar regulation, increases resistance to stress and suppresses inflammation.

Because most Americans eat three meals plus snacks each day, they do not experience the switch, or the suggested benefits.

In the article, Mattson notes that four studies in both animals and people found intermittent fasting also decreased blood pressure, blood lipid levels and resting heart rates.

Evidence is also mounting that intermittent fasting can modify risk factors associated with obesity and diabetes, says Mattson.

Two studies at the University Hospital of South Manchester NHS Foundation Trust of 100 overweight women showed that those on the 5:2 intermittent fasting diet lost the same amount of weight as women who restricted calories, but did better on measures of insulin sensitivity and reduced belly fat than those in the calorie-reduction group.

More recently, Mattson says, preliminary studies suggest that intermittent fasting could benefit brain health too.

A multicenter clinical trial at the University of Toronto in April found that 220 healthy, nonobese adults who maintained a calorie restricted diet for two years showed signs of improved memory in a battery of cognitive tests. While far more research needs to be done to prove any effects of intermittent fasting on learning and memory,

Mattson says if that proof is found, the fasting – or a pharmaceutical equivalent that mimics it – may offer interventions that can stave off neurodegeneration and dementia.

“We are at a transition point where we could soon consider adding information about intermittent fasting to medical school curricula alongside standard advice about healthy diets and exercise,” he says.

Mattson acknowledges that researchers do “not fully understand the specific mechanisms of metabolic switching and that “some people are unable or unwilling to adhere” to the fasting regimens.

But he argues that with guidance and some patience, most people can incorporate them into their lives. It takes some time for the body to adjust to intermittent fasting, and to get beyond initial hunger pangs and irritability that accompany it.

“Patients should be advised that feeling hungry and irritable is common initially and usually passes after two weeks to a month as the body and brain become accustomed to the new habit,” Mattson says.

To manage this hurdle, Mattson suggests that physicians advise patients to gradually increase the duration and frequency of the fasting periods over the course of several months, instead of “going cold turkey.”

As with all lifestyle changes, says Mattson, it’s important for physicians to know the science so they can communicate potential benefits, harms and challenges, and offer support.

With more than 2 in 3 adults suffering with overweight or obesity, Americans are searching for effective weight loss methods [1].

Fasting, called “the next big weight loss fad” [2], has long been integral to many religious and ethnic cultures [3]. Intermittent fasting (IF) has many forms; the basic premise involves taking periodic breaks from eating.

Common forms of IF include fasting for up to 24 hours once or twice a week with ad libitum (ad lib) food intake for the remaining days, which is known as periodic prolonged fasting (PF) or intermittent calorie restriction (ICR) [4]; time-restricted feeding (TRF), such as eating for only 8 hours then fasting for the other 16 hours of the day; and alternate-day fasting (ADF) [5,6].

Most ADF programs involve alternating feast (ad lib intake) and fast days (≤25% of energy needs) with some protocols allowing no caloric intake on fast days [4].

Thus, the degree of fasting varies in ADF based on the specific protocol.

IF continues to gain attention with new evidence from basic science research and clinical trials. This paper reviews these developments.

First, we provide an overview of the key aspects of metabolism involved in fasting. Next, we review clinical trial data of IF outcomes including changes in weight loss and body composition, insulin sensitivity (Si), cardiovascular biomarkers, aging and cognition, psychosocial factors, and the gut microbiome. We review potential cellular mechanisms for these effects including modulation of oxidative stress, inflammation, and autophagy.

Finally, we assess the clinical implications of these results and identify directions for future research.

Overview of Human Metabolism: The Fed-Fast Cycle

Glucose is the primary energy source for most tissues during the day. Fatty acids (FA) represent an alternative fuel source for the most metabolically active organs including the muscle, liver, and brain and rise overnight during fasting.

In 1963, Randle proposed a theory of energy metabolism during feeding and fasting known as the “glucose-fatty acid cycle” whereby glucose and FA compete for oxidation [7].

Since 1963, this cycle and its underlying mechanisms have been elucidated [8].

The fed-fast cycle has four stages: the fed state, the post-absorptive or early fasting state, the fasting state, and the starvation or long-term fast state (Figure 1) [9].

An external file that holds a picture, illustration, etc.
Object name is nihms963293f1.jpg
Figure 1
The fed-fast cycle [915]
This figure illustrates the four stages of the fed-fast cycle. Only the fed and post-absorptive states are relevant to normal eating routines. Based on the IF regimen, an individual often goes through the fed, post-absorptive and fasting states. Additionally, while the figure is cyclic, it is possible to return to the food consumption point at any time.

The Fed-Fast Cycle, Circadian Rhythmicity of FFA and Intermittent Fasting

The circadian clock regulates gene expression and broadly affects various organs and the network of neurohormonal weight control signals [16]. Overnight fasting, or fasting during sleeping hours, is associated with a nocturnal rise in plasma free fatty acids (FFA), ghrelin, growth hormone, and increased hepatic gluconeogenesis [17]. Adipose tissue (AT) orchestrates the cycling of triglycerides (TG) by controlling the uptake, esterification, and release of FFA to meet the metabolic demands of the liver and muscle tissue. Hence, integration of circadian rhythms and eating may be beneficial.Go to:

The Effects of Intermittent Fasting

The following sections summarize the current literature on various effects of IF.

Alterations in Weight and Body Composition

Nearly all IF studies have resulted in some degree of weight loss, ranging from 2.5–9.9% [18,19], and associated fat mass loss. Numerous studies have been conducted on IF (Table 2), but IF protocol, duration, and baseline characteristics of the sample population have varied greatly.

Table 2

This table highlights adult human RCTs studies that meet the following criteria: published between 2003 and 2018; IF evaluated as primary variable; IF regimen greater than 1 week. TRF and PF studies were excluded due to the scope of this paper. The studies are ordered by highest N and longest duration. Abbreviations include N (sample size of completers), F (females), M (males), mAge (mean age), bBMI (baseline BMI), IF (intermittent fasting), ADF (alternate-day fasting), mon (months), wk (weeks), d (day), yo (years old), combo (combination), LDL (low density lipoprotein cholesterol), HDL (high density lipoprotein cholesterol), NS (not statistically significant), FFM (fat fee mass), BP (blood pressure), NR (not reported).

Study PopulationStudy Design
First author, YearabN completers (Female/Male), inclusion criteriac, dropout rate (DR)Groups and characteristics (N, mAged, bBMIe)IF RegimenDurationKey Results
Harvie, 2013[33]N = 115
Women only
Age 20–69
BMI 24.0–45.0 and/or body fat >30%
DR: 11 % in ICR group; 26% in ICR+PF and 33% in DER
ICR (n=37, 45.6±8.3, 29.6±4.1)
ICR+PF (n=38, 48.6±7.3, 31.0±5.7)
CER (n=40, 47.9±7.7, 32.2±5.6)
25% energy needs4 restricted in all, euenergetic groups
ICR without ad lib protein, fat: CR and carb restriction on 2 consecutive d/wk
ICR + protein, fat (ICR+PF): same as ICR but with unlimited protein and fat on restricted days
CER: daily 25% CR
3 mon weight loss, 1 mon weight maintenance↓ weight, body fat in ICR > CER groups↑Si with both ICRLess FFM loss in ICR groupsShort term: ICR superior to CER re: Si and ↓ body fat
Harvie, 2011[28]N = 107
Women only Age 30–45
BMI 24.0–40.0
DR: 21% in ICR group; 13% in CER group
ICR (n=53, 40.1±4.1, 30.7±5.0)
CER (n=54, 40.0±3.9, 30.5±5.2)
25% energy restriction4 as ICR (2d/wk) or CER (7d/wk)6 monICR and CER equally effective for weight lossComparable ↓leptin, free androgen index, RP, total and LDL cholesterol, TG, BP + ↑sex hormone biding globulinModest ↓ in Si, fasting insulin – greater in ICR
Bhutani, 2013[25]N = 83
Age 25–65
BMI 30.0–39.9
DR: 9 dropped out of ADF, 8 out of exercise. No dropouts in exercise or control groups.
ADF + exercise (combo, n=18, 45±5, 35±1)
ADF (n=25, 42±2yo)
Exercise (n=24, 42±2, 35±1)
Control (n=16, 49±2, 35±1)
ADF: 25% energy needs2 fast day, ad lib feast day
Exercise: moderate intensity exercise 3d/wk
12 wk↓ weight in combo, ADF, exercise groups↓ LDL, fat mass, waist circumference; ↑ HDL in combo only
Trepanowski, 2017a [22]N = 79
Age 18–65
BMI 25.0–39.9
DR: 38% in ADF, 29% in CR, 26% in control
ADF (n=25, 46±2, 34±1)
CR (n=29, 44±2, 35±1)
Control (n=25, 44±2, 34±1)
ADF: 25% energy needs1 on fast days, 125% feast day with dietary counseling for first 12 wk
CR: 75% needs1 daily + dietary counseling for first 12 wk only
Control: 100% needs daily; no intervention
4 wk baseline run-in period → 24-wk weight loss intervention period → 24-wk maintenance period↓ weight (−6.8% in ADF and CR at 6 months, 6.0% in ADF and 5.3% in CR at 12 months)↑HDL in ADF at mon 6, not at mon 12↑LDL in ADF at month 12NS differences between groups in BP, heart rate, TG, fasting glucose, fasting insulin, Si, CRP, or homocysteine
Trepanowski, 2017b [23]See Trepanowski, 2017a [22]See Trepanowski, 2017a [22]See Trepanowski, 2017a [22]Only the first 28 weeks of Trepanowski, 2017a [22]↑ FFM:total mass ratio in ADF and CR (NS difference)↓leptin in ADF and CR (NS difference)No change in circulating adiponectin, resistin, IL- 6, or TNF=α in any group
Teng, 2013[90]N = 56
Men only
Age 50–70
BMI: 23.0–29.9
ICR (n=28, 59.6±5.4, 26.8±1.7)
Control (n=28, 59.1±6.2, 26.7±2.3
ICR: 300–500 kcal/d deficit with 2 d/wk Muslim Sunnah fasting. Fasting day included light meal before sunrise, no food and drink during the day (~13 h) and complete meal after sunset Control3 mon↓weight, %fat, energy intake, fat intake, BP, LDL, total cholesterol in ICR↓damage of DNA cells in ICR↑fat intake in controlMaintained or ↑weight, BMI, %fat in control group
Byrne, 2017[19]N = 51
Men only
Age 25–54
BMI 30.0–45.0
ICR (n=26, 39.9±9.2, 34.6±4.2)
CER (n=25, 39.3±6.6, 34.4±3.3)
During ER weeks, 67% energy needs3 for weight maintenance32 wk
Interspersed: 8 x 2-week blocks of CR and 7 x 2- week blocks of energy balance
↓ weight, fat mass to greater degree in ICR↓ REE greater in ICR after adjusting for changes in body composition
Varady, 2011[91]N = 49
Age 35–65
BMI 25.0–39.9
ADF (n=13, 47±2, 32±2)
CR (n=12, 47±3, 32±2)
Exercise (n=12, 46±3, 33±1)
Control (n=12, 46±3, 32±2)
ADF: 75% energy needs2 on fast days, ad lib feast days
CR: 75% energy needs2 daily
Exercise: moderate intensity 3d/wk
Control: usual
12 wk↓ weight in ADF, CR, exercise groups↓ LDL in ADF and CR only; ↑ HDL in exercise only
Keogh, 2014[29]N = 36
Women only Age ≥18
BMI ≥27.0
Healthy or T2D managed by diet alone
DR: 40% in first 8 wk, 20% between 8–52 wk
ICR (n=19, 59.5 ± 8.7, 33.1±3.8)
CER (n=17, 60.8 ± 12.5, 33.0 ± 7.5)
ICR: 1 week ‘normal’ diet followed by 1 wk CR (5500 kJ)
CER: every day CR (5500 kJ)
8 wk weight loss intervention, 12 wk weight loss maintenance↓ weight, waist and hip circumference (NS difference between groups)↑ Healthy Eating Index at 12 mon in CER only
Hussin, 2013[92]N = 31
Males only
Age: 50–70
BMI: 23.0–29.9
DR: 0 subjects in
ADF, 1 in control
FCR (n=16, 59.7±6.6, 26.7±1.8)
Control (n=15, 59.7±6.2, 26.8±2.6)
IF: 300–500 kcal/d reduction from baseline6 + 2 d/wk of Muslim Sunnah fasting; with counseling
Control: ad lib, no counseling
3 mon↓ anger, tension, confusion, weight, BMI, body fat in IF groupNS changes in mean depression scores
Varady, 2013 [93]N = 30
Age 35–65
BMI 20.0–29.9
DR: 6.2% (2 of 32)
ADF (n=15, 47±3, 26±1)
Control (n=15, 48±2, 26±1)
ADF: 25% energy needs2 on fast day (meals provided), ad lib feast day
Control: ad lib daily
12 wk↓ weight, fat mass, TG, leptin in ADF↑ adiponectin, LDL particle size in ADFUnchanged LDL, HDL,
Teng, 2011 [24]N = 25
Men only
Age 50–70
BMI: 23.0–29.9
DR: 14% (4 of 28)
FCR (n=12, 59.3±3.4, 27.0±1.7a)
Control (n=13, 58.3±6.3, 26.5±1.8)
ICR: −300 to −500 kcal/day + 2 days of fasting/wk for 3 mon period
Control: no intervention
3 mon↓ weight, BMI, body fat %, depression in ICR↑ energy component of QOL in ICR
Catenacci, 2016[27]N = 25
Age: 18–55
BMI: ≥30.0
DR: 7 withdrew prior to randomization; all 25 completed intervention
ADF (n=13, 36.9±9.5, 35.8±3.7)
CR (n=12, 42.7±7.9, 39.5±6)
ADF: 0% energy needs5 on fast day, ad lib feast day
Control: 400 kcal/d deficit
8 wk intervention
24 wk follow up
↓ weight in both groups, NS differenceADF group regained more FFM and CR group regained more FM (NS)
Harder- Lauridsen, 2017[94]N=20
Males only
Age: ≥18
BMI: 18.5–2.05
DR: 10% in ADF, 0 in control
ADF (n=10, 23±3.6, NR)
Control (n=10, 24±1.8, NR)
While on bed rest
ADF: 25% energy needs2 on fast days (1 meal/d), 175% needs on feast days (4 meals/d)
Control: 100% needs2 (3 meals/d)
8 daysNS differences in weight, body composition, biomarkers, or glycemic control↓ systolic blood pressure in ADF↓ FFM in both groups

Open in a separate windowaInclusion age in years and inclusion BMI in kg/m2. Mean age (mAge) presented as Mean ± SEM when available. Mean baseline BMI (bBMI) presented as Mean ± SEM when available.bEnergy needs calculated by: 1doubly labeled water technique, 2Mifflin-St. Jeor equation, 3measured REE (indirect calorimetry) x self-reported physical activity level, 4calculated resting metabolic rate x activity factor, 5[(372 + 23.9 X FFM) X 1.5], 6Diet history questionnaire (DHQ)

The literature distinguishes between ADF and ICR regimens. Heilbronn et al. evaluated 22 days of ADF (0% intake on fast days, ad lib feast days) in 16 healthy subjects with normal BMI [18]. ADF resulted in minor weight loss (2.5%), fat loss (4%), and increased fat oxidation [18]. In contrast, Eshghinia and Mohammadzadeh evaluated 6 weeks of ADF (very low-calorie diet (VLCD) on fast days, ad lib feast days) in women with overweight or obesity [20]. ADF led to 7.1% weight loss and visceral fat mass loss (5.7%). Another study assessed the effects of 8 weeks of ADF with either a high- or low-fat diet in 32 women with obesity [21]. Weight, fat mass, and waist circumference decreased similarly in both groups.

When comparing ADF to no-intervention control, ADF resulted in 6.5% weight loss relative to the control group [5]. However, dietary satisfaction is also important to consider when evaluating weight loss methods. In the same study, hunger did not change in either group, but satisfaction and fullness increased in the ADF group only [5]. This is of particular clinical significance, as diets are often not sustainable due to dissatisfaction with dietary restrictions.

An RCT comparing ADF, CR, and no-intervention control found that mean weight loss was not significantly different at 6 or 12 months between ADF and CR, but dropout rate was significantly higher in the ADF group [22]. Mean LDL cholesterol levels were significantly elevated (+11.5mg/dL [95%CI, 1.9–21.1mg/dL]) in the ADF group at month 12 compared to the CR group. A preplanned secondary analysis compared changes in body composition and fat distribution measured by DEXA and MRI at week 24 [23]. There was no significant difference between ADF and CR in the relative amounts of fat mass, FFM, or visceral and subcutaneous fat loss.

In a study comparing ICR and CER in men with obesity, greater weight loss was seen in the ICR group (12.6% vs. 7.2%) [19]. Fat mass loss was also greater in the ICR group (12.3 kg vs. 6.6 kg), but changes in fat free mass (FFM) were similar [19].

Teng et al. evaluated ICR compared to no-intervention control in men (BMI 18.5–29.9 kg/m2) [24]. The ICR group had decreased weight and fat mass, but weight and fat mass increased in the CER group. FFM was similar pre- and post-intervention in both groups. In contrast to these two studies, Bhutani et al. found that only subjects in the ADF plus exercise group experienced decreased fat mass, not those in the ADF or exercise groups alone [25].

To further add complexity to the mixed results, other studies comparing IF and CER have seen similar weight effects in both groups [2629]. For example, Catenacci et al. observed 8.8% weight loss in the ADF group and 6.2% in the CER group after 8 weeks, though the between group difference was only marginally significant [27].

While weight and fat mass decreased in most studies, it is important to consider protocol adherence and dropout rates in IF interventions. Some studies have found that the ADF group ate more than prescribed on fasting days and less than prescribed on feast days [22]. Based on these findings, two questions arise. First, does IF, or simply the intervention itself, lead to weight loss? Secondly, does the ADF intervention become CER in the real-world setting due to difficulty following the protocol? Furthermore, dropout rates have been as high as 40%. Thus, despite the statistical significance of weight loss results, the clinical significance and practicality of sustaining an IF regimen are questionable.

Effects on glucose metabolism and insulin sensitivity

Si may be assessed by several methods, including HOMA-IR and hyperinsulinemic euglycemic clamp [30]. Halberg et al. evaluated Si by hyperinsulinemic euglycemic clamp in 8 heathy men (BMI 25.7 ± 0.4 kg/m2) pre- and post-ADF with 20 hours of fasting [31]. Insulin-mediated glucose uptake was assessed by glucose infusion rate (GIR).

The final clamp was performed after a 36 hour fast. Although subjects maintained stable weight, Si improved, as indicated by significant increases in GIR, adiponectin, and inhibition of insulin-mediated lipolysis. Soeters et al. sought to replicate these results in a crossover study of 8 healthy men who followed a standard diet or ADF with 20 hours of fasting for 2 weeks [32]. Weight remained unchanged. Unlike the Halberg study, glucose uptake and Si were unchanged during the clamp performed 14-hours post-fasting [32].

Thus, it is unknown when Si improves the most post-fasting and if this is a sustainable change, particularly in healthy men. However, a more clinically relevant question is whether IF can benefit subjects with impaired baseline Si.

In a study comparing ADF and CER, there were no between group differences in lipids or Si [27]. This differs from results of a larger randomized controlled trial (RCT), which found that Si and fasting insulin improved more in the ICR group, compared to the CER group, despite similar effects on weight and other biomarkers [28]. A preplanned secondary analysis of a 2017 RCT [22] found that serum leptin decreased similarly in both CR and ADF groups, and HOMA-IR decreased more in the ADF group (−42%) than in the CR group (−18%) [23].

Another RCT reinforced these findings [33]. Subjects were randomized to one of three CR protocols: CER; carbohydrate- and energy-restricted ICR with ad lib protein and fat (IECR+PF); or carbohydrate- and energy-restricted ICR without ad lib protein and fat (IECR) [33]. Both IECR groups experienced greater improvements in Si than the CER group at 3 months. Both groups also experienced a larger reduction in body fat than the CER group, although total weight loss at 3 and 4 months was not significantly different.

Because IF in animal studies were associated with decreased serum glucose and insulin, these beneficial effects were anticipated in humans. However, human trials have shown only stable or decreased fasting insulin with no change in fasting glucose [20,28,3336], which is a difficult endpoint to translate to the clinical setting. Thus, while some animal studies [37] suggest an association between IF and Si, the results may not be extrapolated to humans.

Cardiovascular Effects

Limited literature exists on the cardiovascular effects of IF in humans. A 2010 study in rats found that IF compared to daily CR improves glycemic control and protects the myocardium against ischemia-induced cellular damage and inflammation [38]. ADF in male C57BL/6 mice for 4-weeks was associated with a decreased proportion of visceral fat, increased adiponectin, decreased resistin, and improved lipid profiles [39].

IF also resulted in increased adiponectin prior to and after induced myocardial infarctions [38]. A 2016 crossover study of 10 healthy participants (BMI 25–45 kg/m2) found significant alterations in postprandial glucose and lipid metabolism [40]. The study, which evaluated total (100%) and partial (75%) CR compared to no CR, suggests that CER could alter cardiometabolic risk, independent of weight change [40].

Fasting is part of the Latter-Day Saints (LDS) religious practice. A meta-analysis of two observational studies on a predominantly LDS population found that those who routinely fasted were 35% less likely to develop coronary artery disease (95% CI, 0.46–0.94) and 44% less likely to develop T2D (95% CI, 0.36–0.88) compared to those who followed normal eating patterns [41].

Routine fasting was also associated with a lower BMI. This population had a lower prevalence of smoking, however, which may confound the association between fasting and clinical outcomes. Nonetheless, the findings suggest that IF could also alter cardiometabolic risk factors.

Additionally, a randomized comparison of IF and CER found comparable reductions in leptin, free androgen index, C-reactive protein, total and LDL cholesterol, TG, and blood pressure as well as similar increases in sex hormone binding globulin and insulin-like growth factor (IGF) binding proteins 1 and 2 [28]. These findings reinforce the potential cardioprotective effects of IF, though more studies need to be conducted in humans.

Impact on Aging and cognition

Animal models provide preliminary evidence that CR and IF may delay aging. Evidence includes improved biomarkers, reduced oxidative stress, and preserved memory [4244]. Oxidative stress is an imbalance between the production of reactive oxygen species (ROS) and antioxidant defenses [45].

Both CR and ADF diets reduce age-related deficits in cognitive and motor function in animal models. The combination of CR and IF has been found to promote longevity and increase resistance to age-related diseases in rodents and monkeys [46].

ADF in mice has been shown to reduce serum glucose and insulin and to increase neuronal resistance to injury, even with isocaloric intake and stable weight [47]. Inbred male mice following an ADF regimen have also shown prolonged lifespan under certain conditions, but strong interactions exist between the genotype, age at initiation, and effect of ADF on body weight and aging [48]. While animal models have provided some promising results, the paucity of human studies prohibit extrapolation of these effects to human models.

In a subset of subjects (n=11), Heilbronn et al. found increased muscle gene expression of SIRT1 post-ADF [34]. SIRT1 is an enzyme that may be implicated in human longevity [49]. Additionally, women had slightly impaired glucose response though this did not change in men. Women had unchanged insulin response, though there was a significant reduction in men. Hence, there may be gender differences in the metabolic response to ADF.

The SIRT1 finding is consistent with another study in which human serum collected pre- and post-intervention was used to culture hepatoma cells. Cells that were cultured in post-intervention sera had increased SIRT1 levels and decreased TG. Additionally, post-intervention cells had decreased proliferation, increased stress resistance, and upregulation of longevity-inducing genes, all of which suggest that IF plays a role in aging and longevity [50]. However, a different three week ADF protocol (25% ER on fast days) was not associated with changes in whole-blood SIRT1 RNA [35].

Most studies assessing IF and aging are conducted on animals. Furthermore, evidence regarding biomarkers of aging and cognition is mixed, and the conclusions of these studies cannot yet be generalized to the larger population.

Psychosocial impact

Because long episodes of fasting may lead to large portions of unhealthy foods at the end of the fast, it is questionable whether weight loss benefits of IF can be maintained. Binge eating disorder (BED), which affects 2.8 million Americans, is especially prevalent among individuals with obesity and those seeking weight loss [51]. BED is larger than normal food consumption in a small time period, often accompanied by a loss of control over eating [52]. Some studies suggest that IF may have implications on depression and BED.

Hoddy et al. found that 8 weeks of ADF in 59 subjects with obesity decreased depression and binge eating (p<0.01) [53]. While the decrease in depression and binge eating was statistically significant, it does not appear clinically significant, as the absolute changes were minimal. Additionally, purgative behavior and fear of fatness remain unchanged, although ADF increased restrictive eating and improved perceived body image [53]. It is important to consider whether the decrease in depression and binge eating indicators is clinically significant enough to risk increased restrictive eating. Further, it is essential to define “restrictive eating” consistently among studies, as Bhutani et al. found that in subjects randomized to ADF or ADF plus exercise, restrained eating increased while uncontrolled eating decreased [25].

Despite the acute psychosocial benefits that Hoddy et al. and Bhutani et al. found, research studies should evaluate the long-term associations between IF, BED, and depression in order to minimize risk of negative psychosocial effects. In the interim, CER seems more appropriate for individuals at risk of any eating disorder, including BED.

Interaction with the Gut Microbiome

The microbiome modulates adiposity and protects against the development of obesity-associated metabolic dysfunction. This recent discovery has sparked interest in modulators of microbial balance. Preliminary animal models suggest that IF may be one of these modulators [54]. ADF in mice, compared to isocaloric ad lib intake, induced white adipose tissue (WAT) beiging, weight loss, and changes in the gut microbiota, including an increase in the Firmicutes:Bacteroides ratio [55]. This was associated with improvements in liver steatosis and metabolic syndrome. However, in microbiota-depleted mice, ADF did not improve obesity or liver steatosis, thus suggesting that the gut microbiota is necessary for ADF to show these benefits. Furthermore, isocaloric ADF in mice modulates the gut microbiota, benefiting adiposity; this has been recently reviewed [56].Go to:

Cellular metabolism underlying effects of IF

In addition to its role as an energy carrier, beta-hydroxybutyrate (βOHB) binds to extracellular receptors and inhibits class I histone deacetylases, which may promote resistance to oxidative stress [57,58]. Thus, epigenetic modifications are likely driven by fasting-induced βOHB elevations. Increases in βOHB alter gene expression in nutrient-sensitive pathways that are implicated in longevity. βOHB also has been shown to promote anti-inflammatory effects by blocking activation of the NLRP3 inflammasome [59] and activating a neuroprotective subset of macrophages in the mouse brain [60]. In addition to the association between IF and neuronal resistance, animal studies have found that IF can affect oxidative stress.

Oxidative stress

CR reduces oxidative stress by limiting mitochondrial generation of ROS and increasing endogenous antioxidant activity; this results in reduced oxidative damage to cellular proteins, lipids, and nucleic acids [61,62]. However, IF has mixed effects on oxidative stress in animal models [63]. In theory, IF may induce hormesis, resulting in beneficial adaptive changes that include activation of AMP-activated protein kinase, mitochondrial network and peroxisome remodeling, and increased production of antioxidant enzymes [42,64,65].

In 8 month old mice at high risk of lymphoma, ADF was associated with a significant reduction in lymphoma (0% vs. 33% of controls), decreased spleen mitochondrial ROS generation, and increased antioxidant superoxide dismutase activity [66]. However, Cerqueria reported increased oxidative stress in 8-week-old Sprague-Dawley rats who underwent 32 weeks of ADF [67]. The ADF group had worsened glucose tolerance, lowered adiponectin, and increased insulin receptor nitration and release of ROS in intra-abdominal AT and muscle [67]. Hence unlike long-term CR, long-term ADF may be associated with worsened Si and oxidative stress. Another study further informed these mixed results. One month of ADF in 8-week old Sprague-Dawley rats had complex, tissue-specific effects on ROS balance in rats [68]. For example, biomarkers of oxidative damage were increased in the liver and the brain but were reduced in the heart [68]. Hence, the effects of IF depend on the animal model, age at initiation, and tissue sampled.

Autophagy is a catabolic process of nutrient recycling that is essential for defense against oxidative stress. Nutrient sensing pathways induce autophagy [69]. IF has been shown to restore autophagic function, thereby preserving organelle quality. This restorative function is impaired by insulin resistance [70] and obesity-induced diabetes in mice fed a high fat diet [71]. However, data on the mechanisms of IF in humans are limited. Twenty-three pre-menopausal women (BMI 25–29.9 kg/m2) followed an ICR diet (two days per week of 65% CR) for one menstrual cycle [72]. After the intervention, 196 metabolites increased (including βOHB and acylcarnitine) and 331 metabolites significantly decreased (including succinic acid, alanine, glutamic acid, and tyrosine). This group also compared the effects of their ICR protocol on the metabolome in another group of pre-menopausal women and found many similar trends [73].

Inflammatory effects

Oxidative stress is closely linked to inflammation. Ten subjects with obesity and asthma followed an ADF protocol for 2 months [36]. Body weight decreased a mean 8% and peak expiratory flow and asthma quality of life scores increased [36]. This intervention was associated with significant reductions in inflammatory markers, including TNF-α and ceramides, and markers of oxidative stress, including protein carbonyls and 8-isoprostane.

In mice, IF increases vascular endothelial growth factor (VEGF) in WAT, with associated alternative macrophage activation and WAT beiging [74]. Gene expression of VEGF, alternative macrophage activation, and beige adipocyte-related proteins are also positively correlated in human AT. This suggests that IF may regulate this same pathway.

Fasting is associated with elevations in FFA and ketone bodies, including βOHB, which may have opposing effects on inflammation. Elevated FFA during fasting may activate proinflammatory pathways [75] and reduce Si [76], while elevations in βOHB may activate anti-inflammatory pathways and alter fuel metabolism as reviewed above. Our group is currently conducting a pilot clinical trial on the effects of dietary supplementation of medium chain triglycerides (MCT), which are metabolized into βOHB (NCT02783703). MCT supplementation may activate anti-inflammatory pathways through βOHB without the detriments of elevated FFAs.

FFA released from lipolysis in mast cells may play an important role in eicosanoid release and control of immune activation [77]. Saturated FFA induce an inflammatory response in macrophages while unsaturated FFA do not [78]. Hence, FFA released from lipolysis play an important role in obesity-induced AT inflammation [79], immune regulation [80], and stimulating hepatic VLDL production [81].

Sustained fasting is associated with acute hepatic steatosis and increased insulin resistance [82]. Normal weight subjects who fasted for 72 and 120 hours had increased intramuscular lipids (IMCL) [83,84]. A 60-hour fast in healthy males was associated with elevated IMCL, increased insulin resistance, and a nine-fold elevation in FFA [83]. Prolonged elevations in FFA, combined with metabolic syndrome and insulin resistance, contribute to increasing hepatic IMCL and lipotoxicity, which leads to nonalcoholic steatohepatitis [84]. However, ADF in mice has been shown to induce metabolic changes that protect against steatosis [85]. Increases in ketogenesis during fasting protects against steatohepatitis in mice [86]; thus, IF may have these same protective effects in humans.

The effects of IF on inflammation have been minimally studied in humans. While cellular level mechanisms have been evaluated in animal models, the application in human models is scarce. Cellular analysis and animal models suggest opposing influence of FFA and ketone bodies on inflammation. Despite understanding these cellular mechanisms, it is unclear whether IF has beneficial effects on oxidative stress and inflammation in human.Go to:

Clinical Implications

While several rodent studies have demonstrated the statistical significance of IF on weight loss and metabolic biomarkers, it is important to consider the clinical significance of these findings. For example, while LDL cholesterol levels at month 12 were significantly in the ADF group, it is unlikely that an 11 mg/dl difference would have implications on provider recommendations. Additionally, human studies suggest that IF regimens are difficult to sustain due to dietary restrictions [18,47] and implications on hunger and satisfaction [18,67,87].

Research is not robust enough to suggest that healthcare professionals should be recommending IF to patients as standard practice.

It is unknown which individuals would most benefit from IF and which form of IF is most effective. It is anticipated that IF would most benefit motivated individuals who are able to avoid overeating following fasting periods. Further, individuals who are highly involved in social events may find it difficult to comply with IF regimens, and skipping social events because they occur during planned fasting periods is unlikely to be beneficial or sustainable.

Additionally, the decision to follow an IF regimen depends on the individual’s goals and desired outcomes. For those interested in weight loss methods, CER may be easier and as effective as IF [88]. Those interested in increasing their FFM may benefit more by combining IF with endurance exercise [25].

There may also be potential contraindications to IF, including certain health conditions, medications, psychosocial barriers, and eating practices. Should IF become part of standard practice, a multidisciplinary approach should be used. Collaboration of registered dietitians, physicians, and other essential healthcare providers will ensure the safety of the patient and decrease the possibility of adverse effects such as weight regain, depression, and BED.


Animal models and human trials suggest that IF may have beneficial effects on weight, body composition, cardiovascular biomarkers, and aging. At the cellular level, IF may also increase resistance against oxidative stress, decrease inflammation, and promote longevity. However, studies vary greatly on their definition of IF, the prescribed protocol, and the duration of IF. Additionally, the studies have been conducted in diverse populations with mixed results.

Due to the increasing prevalence of overweight and obesity, Americans are searching for effective weight loss methods. The paucity of research on IF makes it difficult to prescribe IF as a reliable method for successful long-term weight loss and maintenance. However, IF appears to be a viable weight loss method, though CER may be as effective. It is important to consider desired outcomes when choosing whether an IF is an appropriate diet. Given that CR is a proven method of weight loss, more research is needed to assess whether IF is a sustainable treatment for obesity as well as if the benefits of IF are maintained long-term.​

Table 1

Comparison of different types of intermittent fasting

Type of IFDescriptionMetabolic states involved
Alternate day fastingAlternating feast (ad lib intake) and fast days (≤25% of energy needs)Fed, post-absorptive, fasting (short duration, likely <36 hours between meals)
Time- restricted fastingEating only during certain time periods (i.e., 8 hours), then fasting for remaining hours of the dayFed, post-absorptive (maximum duration between meals is usually <16 hours)
Periodic fastingFasting for up to 24 hours once or twice a week with ad lib intake on the remaining daysFed, post-absorptive, fasting (up to 48 hours between meals depending on whether fast days are consecutive)


Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.